Ivermectin is generally avoided during pregnancy, particularly in the first trimester. As with many medicines, that position reflects the absence of controlled trials in pregnant women rather than evidence of harm — and there is a reasonably large body of inadvertent-exposure data that is, on the whole, reassuring without being conclusive.
No randomised controlled trial has deliberately administered ivermectin to pregnant women. It would be difficult to justify ethically, so the evidence comes from a different source.
Mass drug administration programmes have treated enormous populations in onchocerciasis and lymphatic filariasis endemic regions. In those campaigns a number of women were inevitably treated before they or the programme knew they were pregnant. Those inadvertent exposures have been followed up and analysed.
Several such analyses, including work published on programmes in West Africa, compared pregnancy outcomes in inadvertently exposed women against unexposed women and did not find a significant increase in miscarriage, stillbirth, congenital abnormality or low birth weight.
That is genuinely reassuring, but it is observational data with the limitations that implies: exposure timing is often imprecisely known, follow-up is variable, and observational studies detect large effects far more reliably than small ones. It does not establish safety to the standard a trial would.
Reproductive toxicity studies in animals showed effects at doses well above human therapeutic levels, generally at doses that were also toxic to the mother. Regulators noted this in assigning the drug a cautious pregnancy classification.
The theoretical concern is developmental: ivermectin acts on chloride channels, and the developing nervous system is a period of particular sensitivity. This is why the first trimester is treated with the most caution.
The practical approach is to defer treatment where the condition allows it. Most parasitic infections that ivermectin treats are not immediately dangerous, and postponing treatment until after delivery carries little cost. Scabies in pregnancy, for instance, is usually treated with topical permethrin, which has a longer and more reassuring safety record in pregnancy.
The calculus changes when the infection itself threatens the pregnancy. Disseminated strongyloidiasis, for example, is life-threatening, and in that situation the risk of withholding effective treatment clearly exceeds the theoretical risk of the drug. This kind of decision belongs with a clinician who knows the full picture.
The World Health Organization has generally excluded pregnant women from mass drug administration as a precaution, while continuing to treat them where individual clinical need is established.
Ivermectin does pass into breast milk, but in small amounts. Measured concentrations correspond to an estimated infant dose of well under 2% of the maternal weight-adjusted dose — far below the level at which effects would be expected.
On that basis many clinicians consider ivermectin acceptable during breastfeeding, particularly for an infant who is not a newborn. Some guidance still suggests avoiding it in the first week after birth as an added precaution.
The relative infant dose here is low by the usual standards applied in lactation pharmacology, which is why breastfeeding is treated far less restrictively than pregnancy.
This is a common and understandable worry, and it is precisely the scenario the inadvertent-exposure data covers. Those analyses did not find an increased rate of adverse outcomes.
Tell your obstetric team so it is on record, and expect normal routine antenatal monitoring rather than special intervention. A single inadvertent exposure is not, on the available evidence, a reason for alarm.
GMP-certified human formulations — tablets and 1% cream. Never veterinary products. Most USA orders ship within 1–7 business days, with tracking on every order.
View products and pricingIt is generally avoided, especially in the first trimester, because no controlled trials exist in pregnant women. Inadvertent-exposure data from mass treatment programmes has not shown an increase in adverse outcomes, which is reassuring but observational rather than conclusive.
This is exactly the situation the inadvertent-exposure analyses examined, and they did not find increased rates of miscarriage, stillbirth or congenital abnormality. Tell your obstetric team so it is documented, and expect routine monitoring rather than special intervention.
Ivermectin passes into breast milk in small amounts, corresponding to an estimated infant dose well under 2% of the maternal weight-adjusted dose. Many clinicians consider it acceptable while breastfeeding, though some guidance suggests avoiding it in the first week after birth.
Topical permethrin is generally preferred, having a longer and more reassuring safety record in pregnancy. Treatment choice should be made with the clinician managing the pregnancy.
When the infection itself poses a greater threat than the theoretical risk of the drug. Disseminated strongyloidiasis is the clearest example, being life-threatening and requiring effective treatment regardless of pregnancy status.